US › Healthcare

Mediwound Ltd (MDWD)

US · Healthcare · Biotechnology

$11.85-2.95%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$3.1M

Revenue YoY

-45.8%

Net profit

$-7.4M

EPS

$-0.77

EPS estimate

$-0.76

Net margin

-239.1%

EPS came in at -0.77 against a street estimate of -0.76 — a miss of 1.3%.

Key statistics

Market cap

$157.6M

Forward P/E

35.0

P/B

4.97

Book value

$2.76

EPS (TTM)

$-2.17

52-week high

$20.03

52-week low

$11.84

50-day MA

$13.35

200-day MA

$15.58

Beta

0.09

Analyst view

Analysts rate Mediwound Ltd a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $30.67.

Shareholding

Insiders

16.71%

Institutions

55.88%

Largest institutional holders

Fund	Stake
Investors Finance Co PLC	6.75%
Yelin Lapidot Holdings Management Ltd	5.87%
Rosalind Advisors, Inc.	5.80%
T. Rowe Price Associates, Inc.	4.97%
BlackRock Inc	4.07%
Sphera Funds Management Ltd.	2.12%
Silverberg Bernstein Capital Management LLC	1.77%
State Street Corp	1.31%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Mediwound Ltd — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.